Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s)

    The ASTCT Early Career Search Initiative will air on Wednesday, November 16 at 2 pm CDT/ 3pm EST.

    Please join us for the ASTCT Pharmacy SIG Early Career Search Initiative Panel on Wednesday, November 16 at 2 pm CDT/ 3pm EST.  This live session will feature a panel of pharmacists in traditional and non-traditional oncology pharmacy roles discussing their respective career paths. 

    The goal of this session is to help incoming and new practitioners identify strategies and guidance to enhance their career search by engaging with a panel of pharmacists in traditional and non-traditional roles. Audience questions will be welcomed during the Q&A portion of the session. 

    This event is open to all healthcare professionals who are members and non-members of ASTCT. 

    If you have any questions for our panelists, please submit them to info@astct.org with the subject line, 'ASTCT Pharmacy SIG Early Career Search Initiative Q&A.'

    We hope to see you on November 16!


    Panelists: 

    • Kelley Carlstrom, PharmD, BCOP - Founder ELO Collaborative
    • Amber Clemmons PharmD, BCOP, FHOPA - Clinical Professor University of Georgia College of Pharmacy, BMT Clinical Pharmacist at Augusta University Medical Center, PGY2 Oncology Residency Director UGA/AUMC
    • LeAnne Kennedy, PharmD, BCOP, CPP. FHOPA - Atrium Health Wake Forest Baptist PGY2 Oncology Residency Program Director, Pharmacy Clinical Specialist Stem Cell Transplant and Cellular Therapy, HOPA President-Elect
    • Jill Kolesar, PharmD - Markey Cancer Center Director of the Precision Medicine Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Translational Oncology Program, Graduate Faculty at University of Kentucky School of Pharmacy
    • Julianna Roddy-McLean, PharmD, BCOP - Hematology Regional Medical Scientific Director at Merck
  • Contains 4 Component(s)

    This journal club aired live on October 26, 2022, as a part of the expanded ASTCT Journal Club. This webinar consisted of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

    ASTCT October Journal Club Session

    This journal club aired live on October 26, 2022, as a part of the expanded ASTCT Journal Club. This webinar consisted of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

    Presenters & Articles

    Dr. Anna Johnson, University of Kentucky

    Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

    Dr. Loretta Parker, Emory University

    Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant

  • Contains 1 Component(s)

    These are the ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions.

    These are the ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions.

    Please complete this optional survey regarding the shortage here.

  • Contains 2 Component(s)

    The ASTCT webinar, 'Off the Shelf CAR T: a deep dive,' aired on Thursday, October 13, 2022, at 2 PM CDT.

    Join us for the third webinar in the ASTCT 2022 CAR T Webinar Series titled, 'Off the Shelf CAR T: a deep dive'. Drs. Matt Cooper and Swami Iyer will identify available off the shelf CAR T products, review the cell types used, and review the clinical, preclinical data, unique constructs and place in therapy of off the shelf CAR T products. Following their presentations, the session will move into a panel discussion facilitated by Dr. Laurie Davis. 


    Moderator:

    Dr. Laurie Davis; Assistant Professor of Pediatrics, Children's Hospital of San Antonio

    Faculty:

    Dr. Matt Cooper; Co-Founder & Chief Scientific Officer at WUGEN and Assistant Professor of Medicine at Washington University School of Medicine

    Dr. Swaminathan Iyer; Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center


    Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.


  • Contains 4 Component(s)

    Join us on September 28 at 1 PM CT for this Joint ASTCT & NMDP Sickle Cell Webinar in honor of Sickle Cell Awareness Month. This webinar will focus on recent research in the use of hematopoietic cell transplant (HCT) for the treatment of sickle cell disease (SCD), convening a panel of experts to discuss ways to improve access for SCD patients who could benefit from HCT.

    During this interactive roundtable-style webinar, our expert HCT and SCD panelists will discuss some of the latest research and outcomes in HCT for SCD, as well as share models for outreach and engagement between transplant centers and SCD programs. Panelists will further explore the role of HCT in the treatment of SCD and how to ensure access to HCT for these patients as a matter of health equity, including through patient programs like the Sickle Cell Warrior Program and HLA Today. This webinar will be relevant for both transplant centers and community hematologists/oncologists and SCD program providers who refer out for transplant and cellular therapies, discussing the role that all practitioners can play in improving access to HCT. 

    Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PLANNING COMMITTEE MEMBERS

    FACULTY

    Stephen Spellman
    Vice President, Research 
    Senior Scientific Director, CIBMTR-NMDP/Be The Match

    Heather Stefanski, MD, PhD
    Vice President, Medical Services
    NMDP/Be The Match

    Elizabeth Stenger, MD
    Pediatric Hematologist/Oncologist, Bone Marrow Transplant Physician
    Children’s Healthcare of Atlanta

    Ashish Gupta, MD, MPH 
    University of Minnesota

    Samuel Anim, MD
    Pediatric Hematologist/Oncologist
    Sanford Roger Maris Cancer Center, Fargo, ND

    ADDITIONAL PLANNERS

    Alejandro Marinos Velarde, MD
    MD Anderson Cancer Center

    Samantha Watters, MPH
    Research and Education Lead, NMDP/Be The Match

    Kelly Wilson, MSN, RN
    Research/Education Specialist, NMDP/Be The Match

    Karla Dawson, MPH
    Health Equity Analyst, NMDP/Be The Match

    Kyra Newman, MSW
    ASTCT Education Manager

    Jas Chahal, PhD
    Manager of Outcomes and Accreditation
    The France Foundation

    Heather Tarbox, MPH
    Director of Education and Compliance, The France Foundation

    PROGRAM OVERVIEW
    This webinar will focus on recent research in the use of hematopoietic cell transplant (HCT) for the treatment of sickle cell disease (SCD), convening a panel of experts to discuss ways to improve access for SCD patients who could benefit from HCT. Many patients and providers alike are unfamiliar with HCT as a potential curative option for SCD patients. Demystifying transplant among SCD providers and encouraging strong relationships between transplant centers and community providers treating SCD patients can help open up HCT as an option for these patients. Disparities in health care among racial and ethnic groups are well established, and the lack of discussion of HCT among SCD patients and providers presents another example of differential access to care. Several transplant programs who routinely transplant SCD patients are working to make stronger connections with local community SCD treatment programs to help overcome these barriers to care and encourage discussion about HCT’s place in the treatment of SCD. 

    During this interactive roundtable-style webinar, our expert HCT and SCD panelists will discuss some of the latest research and outcomes in HCT for SCD, as well as share models for outreach and engagement between transplant centers and SCD programs. Panelists will further explore the role of HCT in the treatment of SCD and how to ensure access to HCT for these patients as a matter of health equity, including through patient programs like the Sickle Cell Warrior Program and HLA Today. This webinar will be relevant for both transplant centers and community hematologists/oncologists and SCD program providers who refer out for transplant and cellular therapies, discussing the role that all practitioners can play in improving access to HCT. 

    LEARNING OBJECTIVES
    Upon completion of the activity, participants should be able to:
    Identify recent trends in access to and outcomes of HCT for SCD
    Discuss models for outreach and engagement to improve shared, coordinated care between transplant centers treating SCD patients and community hematology/oncology or SCD programs
    Describe the role of HCT in the treatment of SCD 
    Explain how transplant centers and hematology/oncology or SCD providers can work together to improve health equity and access to HCT
    Use patient resources for SCD through the Sickle Cell Warrior Program and HLA Today

    TARGET AUDIENCE
    This activity is intended for physicians and other members of the health care team who care for patients with sickle cell disease.

    INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
    There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the activity, and evaluation form. Your CME certificate will be available for download.

    ACCREDITED PROVIDER 
    This activity is jointly provided by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy (ASTCT). 

    image

    image

    In support of improving patient care, this activity has been planned and implemented by The France Foundation, National Marrow Donor Program, and American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    CREDIT DESIGNATION

    image

    Physician Credit Designation

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other healthcare professionals completing this course will be issued a statement of participation.

    DISCLOSURE POLICY
    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the National Marrow Donor Program (NMDP), and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, NMDP, and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF NMDP, and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF NMDP, and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

    Name  of Individual

    Individual’s Role in Activity

    Name of Commercial Entity

    Nature of Relationship(s)

    Mechanism(s) implemented to resolve conflict of interest

    Alejandro Marinos Velarde, MD

    Planner

    No relevant financial disclosures

    NA

    NA

    Ashish Gupta, MD, MPH

    Planner and Faculty

    No relevant financial disclosures

    NA

    NA

    Elizabeth Stenger, MD

     

    Planner and Faculty

    No relevant financial disclosures

    NA

    NA

    Heather Stefanski, MD, PhD

    Planner and Faculty

    No relevant financial disclosures

    NA

    NA

    Heather Tarbox, MPH

    TFF Staff

    No relevant financial disclosures

    NA

    NA

    Jas Chahal, PhD

    TFF Staff

    No relevant financial disclosures

    NA

    NA

    Karla Dawson, MPH

     

    NMDP Staff

    No relevant financial disclosures

    NA

    NA

    Kelly Wilson, MSN, RN

     

    NMDP Staff

    No relevant financial disclosures

    NA

    NA

    Kyra Newman

    ASTCT Staff

    No relevant financial disclosures

    NA

    NA

    Samantha Watters, MPH

    NMDP Staff

    No relevant financial disclosures

    NA

    NA

    Samuel Anim, MD

     

    Planner and Faculty

    No relevant financial disclosures

    NA

    NA

    Stephen Spellman

    Planner and Faculty

    No relevant financial disclosures

    NA

    NA

    DISCLOSURE OF UNLABELED USE
    TFF, NMDP, and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, NMDP, and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

    DISCLAIMER 
    TFF, NMDP, and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, NMDP, and ASTCT assume no liability for the information herein.

    COPYRIGHT INFORMATION

    Copyright © 2022 The France Foundation, NMDP, and ASTCT. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 

    • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
    • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

    PRIVACY POLICY
    The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

    The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

    Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

    CONTACT INFORMATION
    If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

  • Contains 1 Component(s)

    This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment.

    This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment. 

    Activity Title

    CAR T-Cell Therapy Consults: Navigating a New Landscape

    Topic

    CAR T-Cell Therapy

    Accreditation Type

    Physicians—maximum of 1.50 AMA PRA Category 1 Credit(s)™ and 1.50 ABIM MOC points

    Accreditor

    American Society of Hematology

    Release Date

    9/26/2022

    Expiration Date

    9/25/2023

    Estimated Time to Complete Activity

    90 minutes

    TARGET AUDIENCE
    This educational activity is intended for hematologists, oncologists, and other healthcare team members involved in the treatment of patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and B-cell lymphoma/diffuse large B-cell lymphoma.

    PROGRAM OVERVIEW
    This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment.

    LEARNING OBJECTIVES
    Upon completion of this course, the learners should be able to:
    • Summarize key aspects of approved or emerging CAR T-cell therapies for use in MM, B-ALL, and BCL/DLBCL, including development, mechanism, specific indications, and serious adverse events
    • Select patients who might be appropriate for CAR T-cell therapy 
    • Complete timely and informative referrals to CAR T-cell therapy specialty centers
    • Create a plan that reflects issues to be monitored and addressed post-CAR T-cell therapy in the short- and long-term

    PLANNING COMMITTEE
    Caitlin Costello, MD 
    Associate Professor of Medicine
    UC San Diego Health

    Catherine Lee, MD
    Associate Professor, Internal Medicine
    Huntsman Cancer Center, University of Utah

    Heidi Thompson, PhD
    Medical Director
    The France Foundation

    FACULTY 
    Caitlin Costello, MD 
    Associate Professor of Medicine
    UC San Diego Health

    Catherine Lee, MD
    Associate Professor, Internal Medicine
    Huntsman Cancer Center, University of Utah

    INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
    There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
    Technical Requirements: http://www.francefoundation.com/general-requirements.html
    Credit fulfillment: If you are requesting AMA credit, or a certificate of participation, your certificate will be available for download 

    ACCREDITED PROVIDER 
    This activity has planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Transplantation and Cellular Therapy (ASCT) and the France Foundation. The American Society of Hematology (ASH) is accredited by the ACCME to provide continuing medical education for physicians.

    PHYSICIAN CREDIT DESIGNATION
    The American Society of Hematology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other healthcare professionals completing this course will be issued a statement of participation.

    Maintenance of Certification  
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 ABIM MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    DISCLOSURE POLICY
    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the American Society of Hematology (ASH) and Collaborating Partners (TFF and ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASH, TFF, and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, ASH, TFF, and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ASH, TFF, and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

     

    Name of Individual

     Role in Activity

    Name of Commercial Interest(s)

    Nature of Relationship(s)

    Mechanism(s) implemented to resolve conflict of interest

    Caitlin Costello, MD

    Planning Committee Member, Faculty

    • Bristol Myers Squibb
    • Janssen
    • Pfizer
    • Takeda
    • Non-CE Consultant, Contract Research
    • Non-CE Consultant, Contract Research
    • Non-CE Consultant
    • Non-CE Consultant, Contract Research

    All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member

     

    Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning

    Catherine Lee, MD 

    Planning Committee Member, Faculty

    • Bristol Myers Squibb
    • Frensenius Kabi
    • Incyte Corporation
    • Jazz Pharmaceuticals
    • Kadmon Corporation
    • Kite Pharma
    • McGraw-Hill
    • Non-CE Consultant
    • Non-CE Consultant
    • Non-CE Consultant, Contract Research
    • Non-CE Consultant
    • Non-CE Consultant
    • Non-CE Consultant
    • Royalty

     

    All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member

     

    Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning

    Erika Fox

    TFF Staff

    NA

    NA

    NA

    Heidi Thompson, PhD 

    Planning Committee Member, Content Reviewer

    NA

    NA

    NA

    Disclosure of Unlabeled Use:
    ASH, TFF, and ASTCT requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. There is no discussion of off label products or procedures in this activity. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ASH, TFF, and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

    COMMERCIAL SUPPORT ACKNOWLEDGMENT
    This activity is supported by educational grants from CRISPR Therapeutics, Janssen, Kite Pharma, and Novartis.

    Disclaimer
    ASH, TFF, and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASH, TFF, and ASTCT and the commercial supporter(s) assume no liability for the information herein.

    COPYRIGHT INFORMATION
    Copyright © 2022 The American Society of Hematology. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 

    • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
    • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The American Society of Hematology’s prior written permission 

    PRIVACY POLICY
    The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

    The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

    Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

    CONTACT INFORMATION
    If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.


  • Contains 2 Component(s)

    The ASTCT webinar, 'Relapse after CAR T and mechanisms of relapse after CAR T,' aired on September 9, 2022 at 2 PM CDT.

    On Friday, September 9, 2022, ASTCT is hosting the second webinar in its 2022 CAR T Webinar Series. Join Drs. Eric Smith and Michael Jain as they review data and strategies to prevent relapse post CAR T, review current CAR T outcomes, and discuss possible published and proposed treatment strategies for CAR T relapse. Dr. Smith's presentation will focus on myeloma, and Dr. Jain's will focus on lymphoma. After their presentations, both speakers will answer questions from the audience. 

    Moderator:

    Dr. Mariana Lucena; Regional Medical Science Director, Medexus Pharma

    Faculty:

    Dr. Eric Smith; Director of Translational Research (Immune Effector Cell Therapies) at Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School 

    Dr. Michael Jain; Assistant Member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center


    Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

  • Contains 2 Component(s)

    The ASTCT webinar, 'CAR T Manufacturing,' aired on August 25, 2022 at 1 PM CDT.

    After the success of the 2021 CAR T Webinar Series, ASTCT is excited to announce another six-part CAR T Webinar Series sponsored by Janssen and Legend Biotech for 2022!

    In this hour-long webinar, Dr. Megan Davis, Dr. Andrew Timmons, and Dr. Boro Dropulić discussed aspects of local manufacturing, an overview of navigating regulation in gene and cell therapy, and the place-of-care manufacturing of CAR-T cells. After their presentations, Drs. Davis and Timmons answered audience questions. 

    Moderator:

    Dr. Armin Ghobadi; Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine

    Faculty:

    Dr. Megan (Suhoski) Davis; Director, Product Development Laboratory, University of Pennsylvania

    Dr. Andrew Timmons; Biologist, Office of Tissues and Advanced Therapies, Division of Cellular & Gene Therapies, US Food and Drug Administration

    Dr. Boro Dropulić; Executive Director, Caring Cross

  • Contains 1 Component(s)

    The ASTCT Evusheld Webinar aired on July 27th, 2022 at 2 PM CDT.

    ASTCT has been in talks with the White House and CDC regarding national supply and demand concerns with Evusheld. There is a large supply available, but the supply is underutilized. This webinar will provide broader education to ASTCT members to spread awareness about Evusheld, including understanding how and when to use Evusheld in regards to vaccines with transplant patients.

    Moderator:

    Dr. Zenia Papanicolaou, MD

    Memorial Sloan Kettering Cancer Center


    Faculty:

    Dr. Dianna Howard, MD

    Professor, Hematology and Oncology

    Atrium Health, Wake Forest Baptist

     

    Dr. Aliyah Baluch, MD, MSc, FACP, FIDSA

    Associate Professor, Department of Oncologic Services

    Moffitt Cancer Center


    Alycia Maloney

    ASTCT Director of Government Relations


    White House/CDC Representatives:

    Erin Abramsohn

    Emily Koumans

    Melisa Shah

    Thomas Tsai

  • Contains 1 Component(s)

    Dr. Ayman Qasrawi from the University of Kentucky Markey Cancer Center, discusses treatment options and outcomes for Ph- Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

    This activity is the third in a series of four educational activities on treating relapsed/refractory Ph- acute lymphocytic leukemia. Dr. Ayman Qasrawi from the University of Kentucky Markey Cancer Center, discusses treatment options and outcomes. He introduces a case study highlighting the treatment decisions in a patient with relapsed Ph – ALL.


    Activity Title

    Treatment of Ph- Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

    Topic

    Acute Lymphoblastic Leukemia

    Accreditation Type

    AMA PRA Category 1 Credit(s)

    Release Date

    7/20/22

    Expiration Date

    7/19/23

    Estimated Time to Complete Activity

    30 minutes


    LEARNING OBJECTIVES

    Upon completion of this activity, participants should be able to:

    • Identify patients who could benefit from CD22-directed ADC therapy using current practice guideline recommendations

    Faculty:

    Ayman Qaswari, MD

    Assistant Professor

    Division of Hematology & BMT

    University of Kentucky

    Lexington, KY

    Content Reviewers:

    Kirsten Roblee, MHI, BSN, RN, OCN 

    Administrative Nurse Manager, Oncology Infusion Services

    Dublin Methodist Hospital & Grady Memorial Hospital

    Ohio Health

    Columbus, OH

     

    METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

    Technical Requirements: http://www.francefoundation.co...

    • There are no fees for participating in and receiving credit for this activity
    • Review the activity objectives and CME/CE information
    • Complete the CME/CE activity
    • Complete the online posttest. A score of at least 80% is required to successfully complete this activity. The participant may take the test until successfully passed.
    • Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

    Credit documentation/reporting:

    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

     

    ACCREDITED PROVIDER 

    This activity is provided by The France Foundation. This activity was produced in collaboration with American Society for Transplantation and Cellular Therapy.

     

    TARGET AUDIENCE


    The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.

    STATEMENT OF NEED

    Acute lymphocytic leukemia (ALL) is a heterogeneous malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to crowding of bone marrow elements and other lymphoid organs.[i] While complete remission has improved over the past decades, almost 50% of adult patients will relapse.[ii] Prognosis for patients with relapsed or refractory (R/R) ALL is poor.[iii]

    A number of treatments have been approved for and are in use for ALL, including chemotherapy, radiotherapy, and targeted therapy. Antibody-drug conjugate therapy directed against CD22 with inotuzumab ozogamicin (InO) has been shown in trials to be an effective tool to manage R/R Philadelphia chromosome positive or negative B-cell ALL, but it can be associated with venoocclusive disease (VOD), particularly manifesting in the liver as sinusoidal obstruction syndrome.[iv] The risk of VOD can be higher after hematopoietic stem cell transplantation (HSCT), particularly after certain conditioning regimens, but it is also possible without HSCT.4

    Given that InO is effective, it is important that clinicians have the confidence to use it. Confidence can be improved with education, so clinicians are more familiar with this therapy, its place in guidelines, its adverse events, and how to manage them.

    ACCREDITATION STATEMENT  

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION

    Physicians

    The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses

    Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

    DISCLOSURE POLICY

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

    Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

     

    Disclosures

    The following financial relationships have been disclosed:

     

    Name and Affiliation

     Role in Activity

    Name of Commercial Entity

    Nature of Relationship(s)

    Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity

    Ayman Qasrawi, MD

     

    Planning Committee Member

    NA

    NA

    NA

    Erika Fox

    TFF Staff

    NA

    NA

    NA

    Heather Tarbox, MPH

    TFF Staff

    NA

    NA

    NA

    Heidi Thompson, PhD

    TFF Staff Content Reviewer

    NA

    NA

    NA

    Kirsten Kozub

    TFF Staff

    NA

    NA

    NA

    Kirsten Roblee, MHI, BSN, RN, OCN

    Nurse Planner/Content Reviewer

    NA

    NA

    NA

     

    DISCLOSURE OF UNLABELED USE

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling.

     

    This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    COMMERCIAL SUPPORT ACKNOWLEDGMENT

    This activity is supported by an educational grant from Pfizer.

    DISCLAIMER

    The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

    COPYRIGHT INFORMATION 

     Copyright © 2022 The France Foundation and The American Society for Transplantation and Cellular Therapy. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

    • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
    • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission

     

    PRIVACY POLICY

    The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME. The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you. Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.co...

    CONTACT INFORMATION

    If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

     REFERENCES:

    [i] Puckett Y, Chan O. Acute lymphocytic leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 29, 2021. https://pubmed.ncbi.nlm.nih.gov/29083572

    [ii] Relapse in Acute Lymphoblastic Leukaemia (ALL). Leukemia Care. 2019. Accessed September 13, 2021. https://media.leukaemiacare.org.uk/wp-content/uploads/Relapse-in-Acute-Lymphoblastic-Leukaemia-ALL-Web-Version.pdf

    [iii] DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81. https://pubmed.ncbi.nlm.nih.gov/32769965

    [iv] Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. https://pubmed.ncbi.nlm.nih.gov/29330398